AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

Imatinib Mesilate Equivalent To Imatinib

10 registrations across 1 African market— 8 active

Markets with Imatinib Mesilate Equivalent To Imatinib

Recent registrations

Brand / ProductMarketHolderStatusExpires
NAZZEC 100🇿🇦South AfricaSandoz South Africa (Pty) LtdsuspendedNov 2023
NAZZEC 400🇿🇦South AfricaSandoz South Africa (Pty) LtdsuspendedNov 2023
SUNMATIN 100🇿🇦South AfricaRanbaxy Pharmaceutical (Pty) LtdactiveMay 2018
IMAVEC🇿🇦South AfricaCipla Medpro (Pty) LtdactiveJan 1900
GLEEVEC🇿🇦South AfricaNovartis South Africa (Pty) LtdactiveJan 1900
VATIVIO 400🇿🇦South AfricaNovartis South Africa (Pty) LtdactiveJan 1900
IMATINIB 100 mg ADCO🇿🇦South AfricaAdcock Ingram Critical Care (Pty) LtdactiveJan 1900
VATIVIO FC🇿🇦South AfricaNovartis South Africa (Pty) LtdactiveJan 1900
IMATINIB 400 mg ADCO🇿🇦South AfricaAdcock Ingram Critical Care (Pty) LtdactiveJan 1900
GLEEVEC 400🇿🇦South AfricaNovartis South Africa (Pty) LtdactiveJan 1900

Imatinib Mesilate Equivalent To Imatinib in Africa — Regulatory Overview

Imatinib Mesilate Equivalent To Imatinib is registered across 1 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 8 (80%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.